Literature DB >> 17700236

Periocular infection.

Jurij R Bilyk1.   

Abstract

PURPOSE OF REVIEW: The aim of this article is to acquaint the clinician with advances in the diagnosis and management of periocular cellulitis and to alert physicians to emerging pathogens. RECENT
FINDINGS: The most important, recent infectious disease entity to consider is community-acquired methicillin-resistant Staphylococcus aureus, which is emerging as a significant problem across the country. The potential devastation caused by necrotizing fasciitis is also reviewed, since this diagnosis is easily missed early in its course. A variety of less common and frankly atypical pathogens is presented to remind the clinician that, on occasion, the hoofbeats are indeed a zebra's.
SUMMARY: Periocular cellulitis remains an important and common entity in ophthalmology. The emergence of new pathogens and the resistance to conventional treatment by others are a cause for concern and require an understanding of management strategies.

Entities:  

Mesh:

Year:  2007        PMID: 17700236     DOI: 10.1097/ICU.0b013e3282dd979f

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  4 in total

Review 1.  Orbital and anterior visual pathway infection and inflammation.

Authors:  Roel De Wyngaert; Ingele Casteels; Philippe Demaerel
Journal:  Neuroradiology       Date:  2009-02-17       Impact factor: 2.804

2.  Successful management of bilateral periorbital necrotising fasciitis with ocular involvement.

Authors:  Wida Setiawati; Hinky Hindra Irawan Satari; Yunia Irawati; Made Susiyanti
Journal:  BMJ Case Rep       Date:  2018-03-15

3.  Headache attributable to disorders of the eye.

Authors:  Deborah I Friedman; Lynn K Gordon; Peter A Quiros
Journal:  Curr Pain Headache Rep       Date:  2010-02

Review 4.  Practical Guidance for Clinical Microbiology Laboratories: Diagnosis of Ocular Infections.

Authors:  Sixto M Leal; Kyle G Rodino; W Craig Fowler; Peter H Gilligan
Journal:  Clin Microbiol Rev       Date:  2021-06-02       Impact factor: 50.129

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.